These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 22642390)

  • 1. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.
    Morgenstern A; Bruchertseifer F; Apostolidis C
    Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.
    Kozempel J; Mokhodoeva O; Vlk M
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29510568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications.
    Radchenko V; Schaffer P; Knapp FFR
    Curr Radiopharm; 2018; 11(3):154-155. PubMed ID: 30378473
    [No Abstract]   [Full Text] [Related]  

  • 4. Radioimmunotherapy with alpha-particle emitting radionuclides.
    Zalutsky MR; Pozzi OR
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.
    Bruchertseifer F; Kellerbauer A; Malmbeck R; Morgenstern A
    J Labelled Comp Radiopharm; 2019 Sep; 62(11):794-802. PubMed ID: 31369165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.
    Miederer M; Scheinberg DA; McDevitt MR
    Adv Drug Deliv Rev; 2008 Sep; 60(12):1371-82. PubMed ID: 18514364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
    Lee D; Li M; Bednarz B; Schultz MK
    Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Overview of Targeted Alpha Therapy with
    Morgenstern A; Apostolidis C; Kratochwil C; Sathekge M; Krolicki L; Bruchertseifer F
    Curr Radiopharm; 2018; 11(3):200-208. PubMed ID: 29732998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted alpha therapy with 213Bi.
    Morgenstern A; Bruchertseifer F; Apostolidis C
    Curr Radiopharm; 2011 Oct; 4(4):295-305. PubMed ID: 22202152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative evaluation of Ac225 vs Bi213 as therapeutic radioisotopes for targeted alpha therapy for cancer.
    Allen BJ
    Australas Phys Eng Sci Med; 2017 Jun; 40(2):369-376. PubMed ID: 28342027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of
    Ondrák L; Ondrák Fialová K; Sakmár M; Vlk M; Bruchertseifer F; Morgenstern A; Kozempel J
    Nucl Med Biol; 2024; 132-133():108909. PubMed ID: 38599144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supply and Clinical Application of Actinium-225 and Bismuth-213.
    Morgenstern A; Apostolidis C; Bruchertseifer F
    Semin Nucl Med; 2020 Mar; 50(2):119-123. PubMed ID: 32172796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer.
    Allen BJ
    Australas Radiol; 1999 Nov; 43(4):480-6. PubMed ID: 10901964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An electrochemical generator for the continual supply of
    Forrester R; Dutech G; Akin A; Fassbender ME; Mastren T
    Nucl Med Biol; 2024; 136-137():108941. PubMed ID: 39002499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered liposomes for potential alpha-particle therapy of metastatic cancer.
    Sofou S; Thomas JL; Lin HY; McDevitt MR; Scheinberg DA; Sgouros G
    J Nucl Med; 2004 Feb; 45(2):253-60. PubMed ID: 14960644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use.
    Ma D; McDevitt MR; Finn RD; Scheinberg DA
    Appl Radiat Isot; 2001 Nov; 55(5):667-78. PubMed ID: 11573800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancements in cancer therapy with alpha-emitters: a review.
    Imam SK
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):271-8. PubMed ID: 11516878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Appendix of Radionuclides Used in Targeted Alpha Therapy.
    Ferrier MG; Radchenko V
    J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S58-S65. PubMed ID: 31427258
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes.
    Wilson JJ; Ferrier M; Radchenko V; Maassen JR; Engle JW; Batista ER; Martin RL; Nortier FM; Fassbender ME; John KD; Birnbaum ER
    Nucl Med Biol; 2015 May; 42(5):428-438. PubMed ID: 25684650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and opportunities in developing Actinium-225 radiopharmaceuticals.
    Dhiman D; Vatsa R; Sood A
    Nucl Med Commun; 2022 Sep; 43(9):970-977. PubMed ID: 35950353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.